Diabetes Drug

Prices of 900 formulations are expected to increase to reflect annual change in WPI

Glenmark Pharmaceuticals Ltd on Wednesday said it has launched triple fixed-dose combination Teneligliptin with Pioglitazone and Metformin in India for diabetic patients. This fixed-dose combination offers patients with Type 2 diabetes the convenience of once daily dosing to improve their glycemic control. It is priced at Rs 14.90 per day, thereby reducing the daily cost of therapy by 40 per cent, making it more affordable to the masses, the company said in a statement. It has been launched under the brand name Zita-PioMet, and contains Teneligliptin (20 mg), Pioglitazone (15 mg) and Metformin (500mg/1000mg) in a sustained release (SR) formulation, it added. "Type 2 diabetes patients in India often face issues of beta cell dysfunction along with insulin resistance. In fact, the prevalence of high insulin resistance in India is 38 per cent compared to the global incidence of 15 per cent," Glenmark Pharmaceuticals EVP & Business Head - India Formulations Alok Malik said. The market .

After the anti-diabetic market, India's cardiac market in for a shake-up

Drug firm AstraZeneca India on Tuesday said it has received approval from the country's drug regulator to market anti-diabetes medication Dapagliflozin. The company said it has received approval from the Central Drugs Standard Control Organization (CDCSCO) for the drug indicated for diabetes patients with chronic kidney disease (CKD). Dapagliflozin is the first and only anti-diabetic drug approved to significantly reduce the risk of sustained eGFR (estimated Glomerular Filtration Rate), cardiovascular deaths and hospitalisations due to heart failure in adults with progressive chronic kidney disease, the drug firm said. The approval is applicable for both diabetic and non-diabetic CKD patients, it added. CKD is one of the leading causes of hospitalisation globally and in India, representing a significant clinical and economic burden. "The timely approval of Dapagliflozin from the CDCSCO committee with the additional indication is a huge boost for nephrologists across the country .

Policies assist those already suffering from the disease and most cost only around 20% more

Regulator looking to cap prices of Sitagliptin, Linagliptin and combinations

The widely available diabetes drug metformin may reduce the risk of emergency room visits, hospitalisation, and death from COVID-19 by more than half if taken within four days of the start of the symptoms, according to a study. The researchers from the University of Minnesota in the US noted that metformin, also known as Glucophage, has been used in the 1950s as an anti-viral called "Fluamine." In more recent research, the drug has been found to affect inflammation pathways, they said. Since COVID-19 involves viral inflammation, the research team thought the combination of anti-inflammatory plus antiviral action was intriguing enough to test the drug. "This was really intriguing to us early on when we learned that people who take metformin were catching COVID-19 less and being hospitalised less," said Elaine Lissner, founder of California-based nonprofit Parsemus Foundation. The study, published on Thursday in the New England Journal of Medicine, compared three medications that we

Merck's Sitagliptin set to lose patent this month; around 200 brands from 50 firms may enter the market

Glenmark Pharmaceuticals on Monday said it has launched a novel fixed-dose combination (FDC) of Teneligliptin, with Pioglitazone in India for adults with uncontrolled Type 2 diabetes. Glenmark has launched this FDC under the brand name Zita Plus Pio, which contains Teneligliptin (20 mg) and Pioglitazone (15 mg), to be taken once a day, the company said in a statement. Diabetes is a key area of focus for Glenmark; a pioneer in providing access to the latest treatment options to diabetic patients in India. We are delighted to introduce this novel Zita Plus Pio, which is the first of its kind in India; offering a world-class and affordable treatment option to adult diabetic patients, Glenmark Pharmaceuticals Group Vice President & Head, India Formulations Alok Malik said. Glenmark claimed it is the "first company in India to market the innovative FDC of Teneligliptin + Pioglitazone, which is approved by the DCGI (Drug Controller General of India)" "This fixed-dose combination will be

Zydus Group on Wednesday said it has received final approval from the US health regulator to market diabetes medication Dapagliflozin tablets in the American market. The drug maker has received final approval from the US Food and Drug Administration (USFDA) to market the drug in the strengths of 5 mg and 10 mg. Dapagliflozin is used with a proper diet and exercise programme to control high blood sugar in people with type 2 diabetes. The drug also lowers the risk of heart failure in adults with type 2 diabetes with heart disease. It is also used to lower the risk of further worsening of kidney disease, end-stage kidney disease (ESKD), death due to cardiovascular disease, and hospitalisation for heart failure in adults with chronic kidney disease. Dapagliflozin works by increasing the removal of sugar by kidneys. The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad, Zydus Group stated. The group now has 328 approvals and has so far fi

Glenmark said it has become the first company in the world to launch the fixed dose combination drug in India

The diabetes segment has been growing faster than the country's overall drug market

Respiratory segment and anti-infectives contract; Cardiac, anti-diabetic growth rates plummet

This should reverse the US underperformance in FY15-20 with margins too moving up sharply

Drug firm Zydus Cadila said it has received approval from the US health regulator to market diabetes drug, Empagliflozin and Linagliptin tablets, in the US market

Biocon Biologics CEO says portfolio to form a substantial part of $1 bn revenue target, to roll out insulin Aspart by next year

The Mumbai-based company has received a tentative approval from the USFDA for its Empagliflozin tablets

As per the USFDA, the companies are recalling the product due to deviation from the current good manufacturing practices

The product is therapeutically equivalent to Synjardy tablets of Boehringer Ingelheim Pharmaceuticals, Inc

Both the recalls by the companies are class III recalls